Jonathan Feddock, MD
Radiation Oncology · Lexington, KYNPI 1164685012
Payments from drug & device makers
What this record shows
Angiodynamics, Inc. accounts for 69.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $1,261 and has fallen 97.8% since, to $28 in 2025.
Across 9 payments — averaging $166.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$1K
- Merck$114
- Galvanize Therapeutics, Inc$113
- Regeneron Healthcare Solutions, Inc.$110
- Isoray, Inc$73
- Cumberland Pharmaceuticals, Inc.$25
- plus $28 from 2 others
Across 3 payments — averaging $96,063 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$288K
What the payments were for
- Consulting fees$85057%
- Food & beverage$65143%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 2 | $1,037 |
| Merck | 1 | $114 |
| Galvanize Therapeutics, Inc | 1 | $113 |
| Regeneron Healthcare Solutions, Inc. | 1 | $110 |
| Isoray, Inc | 1 | $73 |
| Cumberland Pharmaceuticals, Inc. | 1 | $25 |
| Pfizer | 1 | $14 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEYTRUDA$114
- ALIYA SYSTEM$113
- LIBTAYO$110
How this compares
$1,501 in reported general payments places this provider in the 70th percentile of 81 radiation oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 80 | $542 |
| Ondansetron OdtOndansetron | 17 | $304 |
| Gabapentin | 12 | $83 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $56 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Lexington
- Eddy YangLexington$20K
- Brian WilliamsLexington$5K
- Graham WarrenLexington$4K
- Nicolas BurnettLexington$2K
- Aradhana KaushalLexington$2K
- Mark BernardLexington$2K
- Laura DownesLexington$1K
- James KnightLexington$1K
- Marcus RandallLexington$1K
- Jacqueline MatarLexington$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.